Hana Biosciences, Inc. Phase 1 Data On Menadione, Its Novel First-in-Class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors, to be Presented At 33rd Hawaii Dermatology Seminar

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced an abstract sponsored by the company, entitled “Summary of Safety and Bioavailability of Menadione Topical Lotion in Normal Subjects,” has been accepted for presentation at the 33rd Hawaii Dermatology Seminar scheduled to be held February 7-13, 2009, in Maui, Hawaii.